VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice

Oncology

Volumn 77, Issue 6, 2010, Pages 385-394

  Bai, Yu ^a   Deng, Hongxin ^b   Yang, Yang ^b   Zhao, Xia ^a   Wei, Yuquan ^b   Xie, Gang ^b   Li, Zhengyu ^a   Chen, Xiancheng ^a   Chen, Lijuan ^b   Wang, Yongsheng ^b   Su, Dan ^a   Qian, Zhiyong ^b   Zhong, Qian ^a   Luo, Hong ^a   Yi, Tao ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Ovarian cancer; RNA interference; Short hairpin RNA; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; LIPOSOME; PLASMID VECTOR; SHORT HAIRPIN RNA; VASCULOTROPIN; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CARCINOMATOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DENSITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL OVARIAN CANCER; MICROVASCULATURE; MOLECULAR CLONING; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; VASCULARIZATION;

ANIMALS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75549086576     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000279385     Document Type: Article

References (43)

1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J: A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329. (Pubitemid 37160865)
2. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159. (Pubitemid 44156488)
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
4. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6. (Pubitemid 20020880)
5. Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-865. (Pubitemid 32273121)
6. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61: 5736-5740. (Pubitemid 32769088)
7. Ohm JE, Carbone DP: VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001; 23: 263-272.
8. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-543. (Pubitemid 29426311)
9. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, Brown LF: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996; 74: 1105-1115. (Pubitemid 26184421)
10. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK: Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002; 8: 3193-3197. (Pubitemid 35155030)
11. Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ, Hsieh CY: Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 1999; 74: 235-240.
12. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-516.
13. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997; 80: 98-106. (Pubitemid 27270925)
14. Oehler MK, Caffier H: Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 2000; 20: 5109-5112. (Pubitemid 32319090)
15. Heidersbach A, Gaspar-Maia A, McManus MT, Ramalho-Santos M: RNA interference in embryonic stem cells and the prospects for future therapies. Gene Ther 2006; 13: 478-486.
16. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC: Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13: 464-477.
17. Hannon GJ, Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378. (Pubitemid 39265678)
18. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216. (Pubitemid 38097589)
19. Lin X, Chen X, Wei Y, Zhao J, Fan L, Wen Y, Wu H, Zhao X: Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 2007; 104: 540-546. (Pubitemid 46240242)
20. Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T: VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 2007; 360: 553-559. (Pubitemid 47048135)
21. Lin XJ, Chen XC, Wang L, Wei YQ, Kan B, Wen YJ, He X, Zhao X: Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials. J Exp Clin Cancer Res 2007; 26: 467-474. (Pubitemid 351157862)
22. Markman M, Walker JL: Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006; 24: 988-994. (Pubitemid 46638854)
23. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD: A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002; 62: 854-859. (Pubitemid 34126964)
24. Tian X, Song S, Wu J, Meng L, Dong Z, Shou C: Vascular endothelial growth factor: Acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 2001; 286: 505-512. (Pubitemid 32916148)
25. Petersen I: Antiangiogenesis, anti-VEGF(R) and outlook. Recent Results Cancer Res 2007; 176: 189-199.
26. Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591.
27. Drewe E, Powell RJ: Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002; 55: 81-85. (Pubitemid 34123904)
28. Kong HL, Crystal RG: Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90: 273-286. (Pubitemid 28182383)
29. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNAliposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311. (Pubitemid 23354418)
30. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K: Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004; 96: 862-872. (Pubitemid 38807607)
31. Wyatt CA, Geoghegan JC, Brinckerhoff CE: Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res 2005; 65: 11101-11108.
32. Shi Y, Zou M, Collison K, Baitei EY, Al- Makhalafi Z, Farid NR, Al-Mohanna FA: Ribonucleic acid interference targeting S100- A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006; 91: 2373-2379. (Pubitemid 43855030)
33. Zhdanov RI, Podobed OV, Vlassov VV: Cationic lipid-DNA complexes-lipoplexes-for gene transfer and therapy. Bioelectrochemistry 2002; 58: 53-64. (Pubitemid 36160467)
34. Young LS, Mautner V: The promise and potential hazards of adenovirus gene therapy. Gut 2001; 48: 733-736. (Pubitemid 32378601)
35. Jiao X, Wang RY, Qiu Q, Alter HJ, Shih JW: Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004; 85: 1545-1553. (Pubitemid 38807751)
36. Zelphati O, Szoka FC Jr: Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996; 93: 11493-11498. (Pubitemid 26347149)
37. Sangare L, Morisset R, Omri A, Ravaoarinoro M: Incorporation rates, stabilities, cytotoxicities and release of liposomal tetracycline and doxycycline in human serum. J Antimicrob Chemother 1998; 42: 831-834. (Pubitemid 29008089)
38. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD: Sphingomyelin- cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995; 72: 896-904.
39. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-3756.
40. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES: A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005; 11: 2662-2669. (Pubitemid 40569467)
41. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59: 5412-5416. (Pubitemid 29526446)
42. Wu Y, Li ZY, Zhao X, Kan B, Wei YQ: Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2. Hum Gene Ther 2006; 17: 941-948. (Pubitemid 46076754)
43. Mulkeen AL, Silva T, Yoo PS, Schmitz JC, Uchio E, Chu E, Cha C: Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch Surg 2006; 141: 367-374.